Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.93 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.93 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.73 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.73 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536364 | 1.00 | DHODH (1.00) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| Cinchophen SCHEMBL29376617 | 0.97 | KDM4E (1.00) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| Cinchophen SCHEMBL25519 | 0.97 | KDM4E (1.00) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| Cinchophen SCHEMBL7588217 | 0.97 | KDM4E (1.00) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| Cinchophen SCHEMBL4805149 | 0.95 | KDM4E (0.97) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| Cinchophen SCHEMBL10757475 | 0.95 | KDM4E (0.97) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| Cinchophen SCHEMBL4464779 | 0.95 | KDM4E (0.97) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| Cinchophen SCHEMBL27543969 | 0.93 | KDM4E (0.93) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| SCHEMBL3237037 | 0.90 | POLB (1.00) | DHODHKDM4EPDE10ALMNASMN1; SMN2 | |
| SCHEMBL8689228 | 0.90 | DHODH (0.82) | DHODHKDM4EPDE10ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117050110-A | GPX4 and DHODH double-inhibition small molecule prodrug compound based on mitochondrial targeting and preparation method and application thereof | 厦门大学 | 2023-11-14 | — | — | CN | claimed |
| US-20110224147-A1 | METHODS AND COMPOSITIONS | Relevare Aust. Pyt. Ltd. (AU) | 2011-09-15 | — | — | US | claimed |
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | claimed |
| EP-2175886-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBio Pty Ltd (AU) | 2010-04-21 | — | — | EP | claimed |
| WO-2010012043-A1 | METHODS AND COMPOSITIONS | CNSBIO PTY LTD (AU) | 2010-02-04 | — | — | WO | claimed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | claimed |
| CN-117327011-A | Quinoline PCSK9 inhibitor and preparation method and application thereof | 山东省分析测试中心 | 2024-01-02 | — | — | CN | disclosed |
| CN-117050110-A | GPX4 and DHODH double-inhibition small molecule prodrug compound based on mitochondrial targeting and preparation method and application thereof | 厦门大学 | 2023-11-14 | — | — | CN | disclosed |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | disclosed |
| WO-2021016464-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CITY OF HOPE (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2020243496-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20110224147-A1 | METHODS AND COMPOSITIONS | Relevare Aust. Pyt. Ltd. (AU) | 2011-09-15 | — | — | US | disclosed |
| US-20100316678-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD. (AU) | 2010-12-16 | — | — | US | disclosed |
| EP-2021005-A1 | METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN | CNSBIO PTY LTD (AU) | 2009-02-11 | — | — | EP | disclosed |
| WO-2009000038-A1 | COMBINATION METHODS AND COMPOSITIONS FOR TREATMENT OF NEUROPATHIC PAIN | CNSBIO PTY LTD (AU) | 2008-12-31 | — | — | WO | disclosed |
| WO-2007128056-A1 | METHODS AND COMPOSITION FOR TREATMENT OF INFLAMMATORY PAIN | CNSBIO PTY LTD (AU) | 2007-11-15 | — | — | WO | disclosed |
| US-5032597-A | Antitumor | DU PONT MERCK PHARMACEUTICAL (US) | 1991-07-16 | — | — | US | disclosed |
| EP-0133244-B1 | PHENYLQUINOLINECARBOXYLIC ACIDS AND DERIVATIVES AS ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-12-05 | — | — | EP | disclosed |
| US-4680299-A | ANTITUMOR AGENTS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0133244-A2 | Phenylquinolinecarboxylic acids and derivatives as antitumor agents | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224147-A1 | METHODS AND COMPOSITIONS | OPRK1, OPRL1, OPRM1 | DHODH 3300/4885KDM4E 1986/4885PDE10A 3536/4885 |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | MSR1, LTB4R2, LTB4R | DHODH 2333/4885KDM4E 4843/4885PDE10A 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.